Project Grant R01CA226531

Onc.ai, Inc. received a $1.69M Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to further develop and validate a deep learning radiomics biomarker for improved early response assessment in metastatic cancer therapy trials. The company is developing SerialCTRS (Serial CT Response Score), a fully automated deep learning model that analyzes baseline and follow-up computed tomography...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...

Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The primary deliverable is the first-in-man clinical imaging study of [77Br]Br-WC-DZ, a bromine-77 ligand targeting...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $591,419 project grant effective May 1, 2026 through April 30, 2031 under the Cancer Treatment Research program (CFDA 93.395) to develop low molecular weight (LMW) theranostic agents targeting multiple myeloma (MM). The research aims to create a first-in-class peptide-based theranostic pair that targets Cluster of Differentiation 38 (CD38) protein, which is uniformly and densely...

Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...

The Department of the Army Medical Command awarded a $685,497 Project Grant to the Regents of the University of California, San Francisco through the Military Medical Research and Development program. The grant will fund a research project from July 2022 through July 2025 to develop GRANZYME B PET imaging as a novel method to assess T-cell activation in response to 177LU-PSMA-617 priming in metastatic castration-resistant prostate cancer. The Military Medical Research and Development program...

Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...